News Releases
View printer-friendly version < < backOVERALL FINANCIAL RESULTS:
SECOND QUARTER |
|||||
($ in Millions, except EPS) |
2020 |
2019 |
% Change |
||
Reported Sales |
$ 18,336 |
$ 20,562 |
(10.8)% |
||
Net Earnings |
3,626 |
5,607 |
(35.3)% |
||
EPS (diluted) |
$ 1.36 |
$ 2.08 |
(34.6)% |
||
Non-GAAP* |
SECOND QUARTER |
||||
($ in Millions, except EPS) |
2020 |
2019 |
% Change |
||
Operational Sales1,2 |
N/A |
N/A |
(9.0)% |
||
Adjusted Operational Sales1,3 |
N/A |
N/A |
(8.8)% |
||
Adjusted Net Earnings1,4 |
4,446 |
6,950 |
(36.0)% |
||
Adjusted EPS (diluted)1,4 |
$ 1.67 |
$ 2.58 |
(35.3)% |
||
1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules |
|||||
2 Excludes the impact of translational currency |
|||||
3 Excludes the net impact of acquisitions and divestitures and translational currency |
|||||
4 Excludes intangible amortization expense and special items |
REGIONAL SALES RESULTS:
SECOND QUARTER |
% Change |
|||||||
Adjusted |
Adjusted |
Adjusted |
Adjusted |
Adjusted |
Adjusted |
Adjusted |
||
|
$ 9,539 |
$ 10,403 |
(8.3)% |
(8.3) |
- |
(8.1) |
||
International |
8,797 |
10,159 |
(13.4)% |
(9.6) |
(3.8) |
(9.4) |
||
Worldwide |
$ 18,336 |
$ 20,562 |
(10.8)% |
(9.0) |
(1.8) |
(8.8) |
||
1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules |
||||||||
2 Excludes the impact of translational currency |
||||||||
3 Excludes the net impact of acquisitions and divestitures and translational currency |
||||||||
Note: values may have been rounded |
SEGMENT SALES RESULTS:
SECOND QUARTER |
% Change |
|||||||
Adjusted |
Adjusted |
Adjusted |
Adjusted |
Adjusted |
Adjusted |
Adjusted |
||
|
$ 3,296 |
$ 3,544 |
(7.0)% |
(3.6) |
(3.4) |
(3.4) |
||
Pharmaceutical |
10,752 |
10,529 |
2.1% |
3.9 |
(1.8) |
3.9 |
||
Medical Devices |
4,288 |
6,489 |
(33.9)% |
(32.7) |
(1.2) |
(32.5) |
||
Worldwide |
$ 18,336 |
$ 20,562 |
(10.8)% |
(9.0) |
(1.8) |
(8.8) |
||
1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules |
||||||||
2 Excludes the impact of translational currency |
||||||||
3 Excludes the net impact of acquisitions and divestitures and translational currency |
||||||||
Note: values may have been rounded |
SEGMENT COMMENTARY:
Pharmaceutical
Pharmaceutical worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 3.9%* driven by STELARA (ustekinumab), a biologic for the treatment of a number of immune-mediated inflammatory diseases, DARZALEX (daratumumab), for the treatment of multiple myeloma, IMBRUVICA (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer, ERLEADA (apalutamide), a next-generation androgen receptor inhibitor for the treatment of patients with prostate cancer, TREMFYA (guselkumab), a biologic for the treatment of adults living with moderate to severe plaque psoriasis, UPTRAVI (selexipag), an oral prostacyclin receptor agonist used to treat pulmonary arterial hypertension and reduce hospitalization, INVEGA SUSTENNA/XEPLION/INVEGA TRINZA/TREVICTA (paliperidone palmitate), long-acting, injectable atypical antipsychotics for the treatment of schizophrenia in adults, and OPSUMIT (macitentan), an oral endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension to delay disease progression. This growth was partially offset by the negative impact of COVID-19 as well as biosimilar and generic competition, with declines primarily in REMICADE (infliximab), a biologic approved for the treatment of a number of immune-mediated inflammatory diseases, international VELCADE (bortezomib), a proteasome inhibitor for the treatment of multiple myeloma, and ZYTIGA (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic castration-resistant prostate cancer.
Medical Devices
Medical Devices worldwide operational sales, excluding the net impact of acquisitions and divestitures, declined by 32.5%* primarily driven by the negative impact of the COVID-19 pandemic and the associated deferral of medical procedures to our Surgery, Orthopaedics, Vision and Interventional Solutions businesses.
NOTABLE NEW ANNOUNCEMENTS IN THE QUARTER:
The information contained in this section should be read in conjunction with
Regulatory |
TREMFYA (guselkumab) – |
|
ZABDENO (Ad26.ZEBOV) and MVABEA (MVA-BN-Filo) – European |
||
DARZALEX (daratumumab) – |
||
SIRTURO (bedaquiline) – |
||
DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) – |
||
IMBRUVICA (ibrutinib) – |
||
Regulatory Submissions |
SIMPONI ARIA (golimumab) – Submission to the |
|
Other |
STELARA (ustekinumab) Discontinuation of Phase 3 LOTUS Study in Systemic |
|
Johnson & Johnson Announces Acceleration of its COVID-19 Vaccine |
||
Biosense Webster Unveils Late-Breaking Results from PRECEPT Study in Patients |
||
1 Subsequent to the quarter |
FULL-YEAR 2020 GUIDANCE:
The estimated impact of the COVID-19 pandemic is included in the guidance below.
July 2020 |
April 2020 |
|
($ in Billions, except EPS) |
||
Adjusted Operational Sales1,2 Change vs. Prior Year |
(0.8%) – 1.0% |
(3.0%) - 0.5% |
Operational Sales2 Change vs. Prior Year |
(1.3%) – 0.5% |
(3.5%) - 0.0% |
Estimated Reported Sales3 Change vs. Prior Year |
(2.6%) – (0.8%) |
(5.5%) - (2.0%) |
Adjusted Operational EPS (Diluted)2,4 Change vs. Prior Year |
(9.6%) - (7.3%) |
(11.9%) - (7.3%) |
Adjusted EPS (Diluted)3,4 Change vs. Prior Year |
(10.7%) – (8.4%) |
(13.6%) - (9.0%) |
1 Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures |
||
2 Non-GAAP financial measure; excludes the impact of translational currency |
||
3 Calculated using Euro Average Rate: |
||
4 Non-GAAP financial measure; excludes intangible amortization expense and special items |
Other modeling considerations will be provided on the webcast.
WEBCAST INFORMATION:
ABOUT
At
NON-GAAP FINANCIAL MEASURES:
*Operational sales growth excluding the impact of translational currency, adjusted operational sales growth excluding the net impact of acquisitions and divestitures and translational currency, as well as adjusted net earnings, adjusted diluted earnings per share and adjusted operational diluted earnings per share excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investors section of the Company's website at quarterly-results.
Copies of the financial schedules accompanying this earnings release are available on the Company's website at quarterly-results. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on
NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS:
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of
|
|||||||||||||||||||
Supplementary Sales Data |
|||||||||||||||||||
(Unaudited; Dollars in Millions) |
SECOND QUARTER |
SIX MONTHS |
|||||||||||||||||
Percent Change |
Percent Change |
||||||||||||||||||
2020 |
2019 |
Total |
Operations |
Currency |
2020 |
2019 |
Total |
Operations |
Currency |
||||||||||
Sales to customers by |
|||||||||||||||||||
geographic area |
|||||||||||||||||||
|
$ 9,539 |
10,403 |
(8.3) |
% |
(8.3) |
- |
|
20,532 |
(1.4) |
% |
(1.4) |
- |
|||||||
|
4,063 |
4,733 |
(14.2) |
(11.5) |
(2.7) |
8,890 |
9,342 |
(4.8) |
(2.1) |
(2.7) |
|||||||||
Western Hemisphere excluding |
1,133 |
1,455 |
(22.1) |
(8.9) |
(13.2) |
2,635 |
2,958 |
(10.9) |
(0.1) |
(10.8) |
|||||||||
|
3,601 |
3,971 |
(9.3) |
(7.7) |
(1.6) |
7,264 |
7,751 |
(6.3) |
(4.9) |
(1.4) |
|||||||||
International |
8,797 |
10,159 |
(13.4) |
(9.6) |
(3.8) |
18,789 |
20,051 |
(6.3) |
(2.9) |
(3.4) |
|||||||||
Worldwide |
|
20,562 |
(10.8) |
% |
(9.0) |
(1.8) |
|
40,583 |
(3.8) |
% |
(2.2) |
(1.6) |
|||||||
Note:Percentages have been calculated using actual, non-rounded |
|
|||||||||||||||||||
Supplementary Sales Data |
|||||||||||||||||||
(Unaudited; Dollars in Millions) |
SECOND QUARTER |
SIX MONTHS |
|||||||||||||||||
Percent Change |
Percent Change |
||||||||||||||||||
2020 |
2019 |
Total |
Operations |
Currency |
2020 |
2019 |
Total |
Operations |
Currency |
||||||||||
Sales to customers by |
|||||||||||||||||||
segment of business |
|||||||||||||||||||
|
|||||||||||||||||||
|
$ 1,557 |
1,537 |
1.3 |
% |
1.3 |
- |
$ 3,297 |
2,975 |
10.8 |
% |
10.8 |
- |
|||||||
International |
1,739 |
2,007 |
(13.4) |
(7.4) |
(6.0) |
3,624 |
3,887 |
(6.8) |
(1.9) |
(4.9) |
|||||||||
3,296 |
3,544 |
(7.0) |
(3.6) |
(3.4) |
6,921 |
6,862 |
0.9 |
3.6 |
(2.7) |
||||||||||
Pharmaceutical |
|||||||||||||||||||
|
6,120 |
5,783 |
5.8 |
5.8 |
- |
12,181 |
11,365 |
7.2 |
7.2 |
- |
|||||||||
International |
4,632 |
4,746 |
(2.4) |
1.4 |
(3.8) |
9,705 |
9,408 |
3.2 |
6.7 |
(3.5) |
|||||||||
10,752 |
10,529 |
2.1 |
3.9 |
(1.8) |
21,886 |
20,773 |
5.4 |
7.0 |
(1.6) |
||||||||||
Medical Devices |
|||||||||||||||||||
|
1,862 |
3,083 |
(39.6) |
(39.6) |
- |
4,760 |
6,192 |
(23.1) |
(23.1) |
- |
|||||||||
International |
2,426 |
3,406 |
(28.8) |
(26.4) |
(2.4) |
5,460 |
6,756 |
(19.2) |
(16.8) |
(2.4) |
|||||||||
4,288 |
6,489 |
(33.9) |
(32.7) |
(1.2) |
10,220 |
12,948 |
(21.1) |
(19.8) |
(1.3) |
||||||||||
|
9,539 |
10,403 |
(8.3) |
(8.3) |
- |
20,238 |
20,532 |
(1.4) |
(1.4) |
- |
|||||||||
International |
8,797 |
10,159 |
(13.4) |
(9.6) |
(3.8) |
18,789 |
20,051 |
(6.3) |
(2.9) |
(3.4) |
|||||||||
Worldwide |
|
20,562 |
(10.8) |
% |
(9.0) |
(1.8) |
|
40,583 |
(3.8) |
% |
(2.2) |
(1.6) |
|||||||
Note:Percentages have been calculated using actual, non-rounded |
|
|||||||||
Condensed Consolidated Statement of Earnings |
|||||||||
(Unaudited; in Millions Except Per Share Figures) |
SECOND QUARTER |
||||||||
2020 |
2019 |
Percent |
|||||||
Percent |
Percent |
Increase |
|||||||
Amount |
to Sales |
Amount |
to Sales |
(Decrease) |
|||||
Sales to customers |
|
100.0 |
|
100.0 |
(10.8) |
||||
Cost of products sold |
6,579 |
35.9 |
6,940 |
33.8 |
(5.2) |
||||
Gross Profit |
11,757 |
64.1 |
13,622 |
66.2 |
(13.7) |
||||
Selling, marketing and administrative expenses |
4,993 |
27.2 |
5,546 |
27.0 |
(10.0) |
||||
Research and development expense |
2,707 |
14.8 |
2,666 |
13.0 |
1.5 |
||||
In-process research and development |
6 |
0.0 |
- |
- |
|||||
Interest (income) expense, net |
26 |
0.2 |
(5) |
0.0 |
|||||
Other (income) expense, net |
24 |
0.1 |
(1,683) |
(8.2) |
|||||
Restructuring |
61 |
0.3 |
57 |
0.2 |
|||||
Earnings before provision for taxes on income |
3,940 |
21.5 |
7,041 |
34.2 |
(44.0) |
||||
Provision for taxes on income |
314 |
1.7 |
1,434 |
6.9 |
(78.1) |
||||
Net earnings |
$ 3,626 |
19.8 |
$ 5,607 |
27.3 |
(35.3) |
||||
Net earnings per share (Diluted) |
$ 1.36 |
$ 2.08 |
(34.6) |
||||||
Average shares outstanding (Diluted) |
2,665.5 |
2,691.7 |
|||||||
Effective tax rate |
8.0 |
% |
20.4 |
% |
|||||
Adjusted earnings before provision for taxes and net earnings (1) |
|||||||||
Earnings before provision for taxes on income |
$ 5,337 |
29.1 |
$ 8,614 |
41.9 |
(38.0) |
||||
Net earnings |
$ 4,446 |
24.2 |
$ 6,950 |
33.8 |
(36.0) |
||||
Net earnings per share (Diluted) |
$ 1.67 |
$ 2.58 |
(35.3) |
||||||
Effective tax rate |
16.7 |
% |
19.3 |
% |
|||||
(1)See Reconciliation of Non-GAAP Financial Measures. |
|
|||||||||
Condensed Consolidated Statement of Earnings |
|||||||||
(Unaudited; in Millions Except Per Share Figures) |
SIX MONTHS |
||||||||
2020 |
2019 |
Percent |
|||||||
Percent |
Percent |
Increase |
|||||||
Amount |
to Sales |
Amount |
to Sales |
(Decrease) |
|||||
Sales to customers |
|
100.0 |
|
100.0 |
(3.8) |
||||
Cost of products sold |
13,641 |
35.0 |
13,555 |
33.4 |
0.6 |
||||
Gross Profit |
25,386 |
65.0 |
27,028 |
66.6 |
(6.1) |
||||
Selling, marketing and administrative expenses |
10,196 |
26.1 |
10,765 |
26.5 |
(5.3) |
||||
Research and development expense |
5,287 |
13.5 |
5,524 |
13.6 |
(4.3) |
||||
In-process research and development |
6 |
0.0 |
890 |
2.2 |
|||||
Interest (income) expense, net |
(16) |
0.0 |
(2) |
0.0 |
|||||
Other (income) expense, net |
(655) |
(1.7) |
(1,705) |
(4.2) |
|||||
Restructuring |
119 |
0.3 |
93 |
0.3 |
|||||
Earnings before provision for taxes on income |
10,449 |
26.8 |
11,463 |
28.2 |
(8.8) |
||||
Provision for taxes on income |
1,027 |
2.7 |
2,107 |
5.1 |
(51.3) |
||||
Net earnings |
$ 9,422 |
24.1 |
$ 9,356 |
23.1 |
0.7 |
||||
Net earnings per share (Diluted) |
$ 3.53 |
$ 3.47 |
1.7 |
||||||
Average shares outstanding (Diluted) |
2,671.0 |
2,697.0 |
|||||||
Effective tax rate |
9.8 |
% |
18.4 |
% |
|||||
Adjusted earnings before provision for taxes and net earnings (1) |
|||||||||
Earnings before provision for taxes on income |
|
32.2 |
|
38.1 |
(18.7) |
||||
Net earnings |
|
27.2 |
|
31.1 |
(15.9) |
||||
Net earnings per share (Diluted) |
$ 3.97 |
$ 4.68 |
(15.2) |
||||||
Effective tax rate |
15.7 |
% |
18.5 |
% |
|||||
(1)See Reconciliation of Non-GAAP Financial Measures. |
|
||||||||
Reconciliation of Non-GAAP Financial Measures |
||||||||
Second Quarter |
Six Months Ended |
|||||||
(Dollars in Millions Except Per Share Data) |
2020 |
2019 |
2020 |
2019 |
||||
Net Earnings, after tax- as reported |
|
|
|
|
||||
Pre-tax Adjustments |
||||||||
Intangible Asset Amortization expense |
1,127 |
1,118 |
2,245 |
2,248 |
||||
Litigation expense, net |
613 |
409 |
733 |
832 |
||||
IPR&D |
6 |
- |
6 |
890 |
||||
Restructuring related |
115 |
142 |
233 |
232 |
||||
Acquisition and Integration related ¹ |
29 |
55 |
(933) |
122 |
||||
Unrealized (gains)/losses on securities |
(533) |
(148) |
(206) |
(306) |
||||
Medical Device Regulation 2 |
37 |
- |
51 |
- |
||||
Other |
3 |
(3) |
3 |
- |
||||
Tax Adjustments |
||||||||
Tax impact on special item adjustments 3 |
(253) |
(230) |
(520) |
(763) |
||||
Tax legislation and related impacts |
(324) |
- |
(434) |
- |
||||
Adjusted Net Earnings, after tax |
|
|
|
|
||||
Average shares outstanding (Diluted) |
2,665.5 |
2,691.7 |
2,671.0 |
2,697.0 |
||||
Adjusted net earnings per share (Diluted) |
|
|
|
|
||||
Operational adjusted net earnings per share (Diluted) |
|
|
||||||
Notes: |
||||||||
1 |
Acquisition and integration related costs for the six months of 2020 primarily includes a |
|||||||
2 |
European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company's |
|||||||
3 |
The tax impact related to special item adjustments reflects the current and deferred income taxes associated |
|
||||||||
Reconciliation of Non-GAAP Financial Measure |
||||||||
Adjusted Operational Sales Growth |
||||||||
SECOND QUARTER 2020 ACTUAL vs. 2019 ACTUAL |
||||||||
Segments |
||||||||
|
Pharmaceutical |
Medical Devices |
Total |
|||||
WW As Reported |
(7.0)% |
2.1% |
(33.9)% |
(10.8)% |
||||
U.S. |
1.3% |
5.8% |
(39.6)% |
(8.3)% |
||||
International |
(13.4)% |
(2.4)% |
(28.8)% |
(13.4)% |
||||
WW Currency |
(3.4) |
(1.8) |
(1.2) |
(1.8) |
||||
U.S. |
- |
- |
- |
- |
||||
International |
(6.0) |
(3.8) |
(2.4) |
(3.8) |
||||
WW Operational |
(3.6)% |
3.9% |
(32.7)% |
(9.0)% |
||||
U.S. |
1.3% |
5.8% |
(39.6)% |
(8.3)% |
||||
International |
(7.4)% |
1.4% |
(26.4)% |
(9.6)% |
||||
General Surgery |
||||||||
Advanced Sterilization Products |
0.1 |
0.1 |
||||||
U.S. |
0.0 |
0.0 |
||||||
International |
0.3 |
0.2 |
||||||
|
||||||||
Baby Center |
0.3 |
0.0 |
||||||
U.S. |
0.7 |
0.1 |
||||||
International |
0.0 |
0.0 |
||||||
All Other Acquisitions and Divestitures |
0.0 |
0.0 |
0.1 |
0.1 |
||||
U.S. |
0.0 |
0.0 |
0.1 |
0.0 |
||||
International |
(0.1) |
0.1 |
0.0 |
0.0 |
||||
WW Adjusted Operational |
(3.4)% |
3.9% |
(32.5)% |
(8.8)% |
||||
U.S. |
2.0% |
5.8% |
(39.5)% |
(8.1)% |
||||
International |
(7.5)% |
1.5% |
(26.1)% |
(9.4)% |
||||
Note: Percentages are based on actual, non-rounded figures and may not sum |
|
||||||||
Reconciliation of Non-GAAP Financial Measure |
||||||||
Adjusted Operational Sales Growth |
||||||||
SIX MONTHS 2020 ACTUAL vs. 2019 ACTUAL |
||||||||
Segments |
||||||||
|
Pharmaceutical |
Medical Devices |
Total |
|||||
WW As Reported |
0.9% |
5.4% |
(21.1)% |
(3.8)% |
||||
U.S. |
10.8% |
7.2% |
(23.1)% |
(1.4)% |
||||
International |
(6.8)% |
3.2% |
(19.2)% |
(6.3)% |
||||
WW Currency |
(2.7) |
(1.6) |
(1.3) |
(1.6) |
||||
U.S. |
- |
- |
- |
- |
||||
International |
(4.9) |
(3.5) |
(2.4) |
(3.4) |
||||
WW Operational |
3.6% |
7.0% |
(19.8)% |
(2.2)% |
||||
U.S. |
10.8% |
7.2% |
(23.1)% |
(1.4)% |
||||
International |
(1.9)% |
6.7% |
(16.8)% |
(2.9)% |
||||
|
||||||||
Dr. Ci Labo - |
(0.2) |
0.0 |
||||||
U.S. |
0.0 |
0.0 |
||||||
International |
(0.4) |
(0.1) |
||||||
General Surgery |
||||||||
Advanced Sterilization Products |
1.0 |
0.4 |
||||||
U.S. |
1.1 |
0.4 |
||||||
International |
0.9 |
0.4 |
||||||
|
||||||||
Baby Center |
0.3 |
0.0 |
||||||
U.S. |
0.7 |
0.1 |
||||||
International |
0.0 |
0.0 |
||||||
All Other Acquisitions and Divestitures |
(0.1) |
0.1 |
0.0 |
0.0 |
||||
U.S. |
0.0 |
0.1 |
0.0 |
0.1 |
||||
International |
(0.2) |
0.0 |
0.0 |
0.0 |
||||
WW Adjusted Operational |
3.6% |
7.0% |
(18.8)% |
(1.7)% |
||||
U.S. |
11.5% |
7.2% |
(22.0)% |
(0.8)% |
||||
International |
(2.5)% |
6.7% |
(15.9)% |
(2.6)% |
||||
Note: Percentages are based on actual, non-rounded figures and may not sum |
REPORTED SALES vs. PRIOR PERIOD ($MM) |
REPORTED SALES vs. PRIOR PERIOD ($MM) |
|||||||||||||||||||
SECOND QUARTER |
SIX MONTHS |
|||||||||||||||||||
% Change |
% Change |
|||||||||||||||||||
2020 |
2019 |
Reported |
Operational (1) |
Currency |
2020 |
2019 |
Reported |
Operational (1) |
Currency |
|||||||||||
CONSUMER HEALTH SEGMENT (2,3) |
||||||||||||||||||||
|
||||||||||||||||||||
US |
$ 96 |
99 |
-3.5% |
-3.5% |
- |
$ 188 |
186 |
1.2% |
1.2% |
- |
||||||||||
Intl |
260 |
344 |
-24.3% |
-16.6% |
-7.7% |
529 |
651 |
-18.7% |
-12.6% |
-6.1% |
||||||||||
WW |
356 |
443 |
-19.7% |
-13.6% |
-6.1% |
717 |
837 |
-14.3% |
-9.5% |
-4.8% |
||||||||||
|
||||||||||||||||||||
US |
170 |
155 |
9.7% |
9.7% |
- |
346 |
306 |
12.9% |
12.9% |
- |
||||||||||
Intl |
227 |
234 |
-2.8% |
4.0% |
-6.8% |
446 |
450 |
-0.8% |
4.6% |
-5.4% |
||||||||||
WW |
397 |
389 |
2.2% |
6.3% |
-4.1% |
792 |
756 |
4.8% |
8.0% |
-3.2% |
||||||||||
OTC |
||||||||||||||||||||
US |
627 |
484 |
29.6% |
29.6% |
- |
1,316 |
991 |
32.8% |
32.8% |
- |
||||||||||
Intl |
522 |
580 |
-10.1% |
-5.0% |
-5.1% |
1,181 |
1,160 |
1.8% |
6.0% |
-4.2% |
||||||||||
WW |
1,149 |
1,064 |
7.9% |
10.7% |
-2.8% |
2,497 |
2,151 |
16.1% |
18.3% |
-2.2% |
||||||||||
SKIN HEALTH / BEAUTY(4) |
||||||||||||||||||||
US |
536 |
663 |
-19.2% |
-19.2% |
- |
1,195 |
1,251 |
-4.5% |
-4.5% |
- |
||||||||||
Intl |
471 |
539 |
-12.5% |
-8.2% |
-4.3% |
929 |
1,041 |
-10.7% |
-7.4% |
-3.3% |
||||||||||
WW |
1,007 |
1,202 |
-16.2% |
-14.3% |
-1.9% |
2,124 |
2,292 |
-7.3% |
-5.8% |
-1.5% |
||||||||||
WOMEN'S HEALTH |
||||||||||||||||||||
US |
3 |
3 |
-2.9% |
-2.9% |
- |
7 |
6 |
14.3% |
14.3% |
- |
||||||||||
Intl |
199 |
250 |
-20.4% |
-12.0% |
-8.4% |
427 |
472 |
-9.6% |
-2.1% |
-7.5% |
||||||||||
WW |
202 |
253 |
-20.1% |
-11.8% |
-8.3% |
434 |
478 |
-9.3% |
-1.9% |
-7.4% |
||||||||||
WOUND CARE / OTHER |
||||||||||||||||||||
US |
126 |
132 |
-4.7% |
-4.7% |
- |
245 |
234 |
4.7% |
4.7% |
- |
||||||||||
Intl |
59 |
61 |
-2.4% |
3.7% |
-6.1% |
111 |
114 |
-1.9% |
2.8% |
-4.7% |
||||||||||
WW |
185 |
193 |
-4.0% |
-2.1% |
-1.9% |
356 |
348 |
2.6% |
4.1% |
-1.5% |
||||||||||
TOTAL CONSUMER HEALTH |
||||||||||||||||||||
US |
1,557 |
1,537 |
1.3% |
1.3% |
- |
3,297 |
2,975 |
10.8% |
10.8% |
- |
||||||||||
Intl |
1,739 |
2,007 |
-13.4% |
-7.4% |
-6.0% |
3,624 |
3,887 |
-6.8% |
-1.9% |
-4.9% |
||||||||||
WW |
$ 3,296 |
3,544 |
-7.0% |
-3.6% |
-3.4% |
$ 6,921 |
6,862 |
0.9% |
3.6% |
-2.7% |
||||||||||
See footnotes at end of schedule |
REPORTED SALES vs. PRIOR PERIOD ($MM) |
REPORTED SALES vs. PRIOR PERIOD ($MM) |
|||||||||||||||||||||||
SECOND QUARTER |
SIX MONTHS |
|||||||||||||||||||||||
% Change |
% Change |
|||||||||||||||||||||||
PHARMACEUTICAL SEGMENT (2,5) |
2020 |
2019 |
Reported |
Operational (1) |
Currency |
2020 |
2019 |
Reported |
Operational (1) |
Currency |
||||||||||||||
IMMUNOLOGY |
||||||||||||||||||||||||
US |
$ 2,362 |
2,379 |
-0.7% |
-0.7% |
- |
$ 4,772 |
4,542 |
5.1% |
5.1% |
- |
||||||||||||||
Intl |
1,161 |
1,087 |
6.8% |
11.0% |
-4.2% |
2,389 |
2,175 |
9.8% |
13.7% |
-3.9% |
||||||||||||||
WW |
3,523 |
3,466 |
1.6% |
3.0% |
-1.4% |
7,161 |
6,717 |
6.6% |
7.9% |
-1.3% |
||||||||||||||
REMICADE |
||||||||||||||||||||||||
US |
593 |
801 |
-25.8% |
-25.8% |
- |
1,218 |
1,575 |
-22.7% |
-22.7% |
- |
||||||||||||||
US Exports (6) |
133 |
62 |
* |
* |
- |
243 |
138 |
75.7% |
75.7% |
- |
||||||||||||||
Intl |
208 |
244 |
-14.5% |
-8.7% |
-5.8% |
464 |
496 |
-6.4% |
-1.6% |
-4.8% |
||||||||||||||
WW |
935 |
1,107 |
-15.5% |
-14.2% |
-1.3% |
1,925 |
2,209 |
-12.9% |
-11.8% |
-1.1% |
||||||||||||||
SIMPONI / SIMPONI ARIA |
||||||||||||||||||||||||
US |
256 |
281 |
-8.7% |
-8.7% |
- |
528 |
544 |
-2.9% |
-2.9% |
- |
||||||||||||||
Intl |
289 |
282 |
2.6% |
6.8% |
-4.2% |
547 |
543 |
0.8% |
4.8% |
-4.0% |
||||||||||||||
WW |
546 |
563 |
-3.0% |
-0.9% |
-2.1% |
1,075 |
1,087 |
-1.1% |
1.0% |
-2.1% |
||||||||||||||
STELARA |
||||||||||||||||||||||||
US |
1,138 |
1,058 |
7.5% |
7.5% |
- |
2,355 |
1,940 |
21.4% |
21.4% |
- |
||||||||||||||
Intl |
558 |
499 |
11.9% |
15.5% |
-3.6% |
1,161 |
1,022 |